WO2025248485 - PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/248485
Publication Date
04.12.2025
International Application No.
PCT/IB2025/055562
International Filing Date
29.05.2025
Title **
[English]
PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
[French]
COMPOSITIONS PHARMACEUTIQUES ET LEURS MÉTHODES D'UTILISATION
Applicants **
IDRX, INC.
Inventors
MAZAIK, Debra
MEDENDORP, Clare
KADAMBI, Vivek
CHRISTO, Jessica
KIM, Sean
LYDON, Nicholas
DEMETRI, George
AUSPITZ, Ben
Priority Data
63/654,708
31.05.2024
US
63/677,840
31.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3221 | |
| EPO | Filing, Examination, Granting | 22453 | |
| Japan | Filing, Examination, Granting | 2923 | |
| South Korea | Filing, Examination, Granting | 3675 | |
| USA | Filing, Examination, Granting | 8740 |
Total:
41,012
Contact Us
Abstract[English]
The present disclosure relates to pharmaceutical compositions and methods for treating conditions associated with aberrant KIT activity (e.g., cancer). The pharmaceutical compositions and methods described herein generally comprise a compound of Formula I.[French]
La présente divulgation concerne des compositions pharmaceutiques et des méthodes de traitement d'états associés à une activité aberrante de KIT (par exemple, le cancer). Les compositions pharmaceutiques et les méthodes décrites ici comprennent généralement un composé de formule I.